FDAnews
www.fdanews.com/articles/133958-aveo-pharmaceuticals-starts-exploratory-biomarker-trial-enrollment

Aveo Pharmaceuticals Starts Exploratory Biomarker Trial Enrollment

February 2, 2011
Cambridge-based AVEO Pharmaceuticals Inc. said it has started enrolling patients in a Phase II exploratory biological marker study of tivozanib, its lead treatment for renal cell carcinoma.
Mass High Tech